The Use Of Implantable Cardioverter-Defibrillator Therapy In Patients Who Are Not Included Or Not Well Represented In Clinical Trials – HRS/ACC/AHA Joint Consensus Statement

AHA Science News

HRS/ACC/AHA Expert Consensus Statement on the Use of ICD Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials

  • The use of implantable cardioverter-defibrillator (ICD) therapy is a widely accepted and important treatment for patients with cardiovascular disease who are at risk for life-threatening ventricular arrhythmias.
  • Situations still exist that aren’t addressed by existing guidelines, which are limited to those specific populations in the trials included in those guidelines.
  • This joint consensus statement helps identify those patients who will receive optimal benefit from the timely use of ICD therapy.

    Read the full article in Circulation
    [published online ahead of print May 9, 2014]. Circulation. doi: 10.1161/CIR.0000000000000056.

Supporting Materials
Other Resources
Related Science 
Posted by Stacy AHA Science on May 9, 2014 1:29 PM America/Chicago